Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship for...

Full description

Bibliographic Details
Main Authors: Thomas Rodier, Alicja Puszkiel, Evelina Cardoso, David Balakirouchenane, Céline Narjoz, Jennifer Arrondeau, Vincent Fallet, Nihel Khoudour, Monia Guidi, Michel Vidal, Xavier Declèves, Chantal Csajka, Jérôme Alexandre, Jacques Cadranel, Elizabeth Fabre, Marie Wislez, François Goldwasser, Benoit Blanchet
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Pharmaceutics
Subjects:
osimertinib
non-small-cell lung cancer
pharmacokinetics
pharmacodynamics
Online Access:https://www.mdpi.com/1999-4923/14/9/1844

Internet

https://www.mdpi.com/1999-4923/14/9/1844

Similar Items